Evidence map›Paper›PMID 37312613›Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2024

Particles and Prejudice: Nanomedicine Approaches to Reducing Health Disparities in Endometrial Cancer.

Claire E Rowlands, Abigail M Folberg, Zachary K Beickman, Eric J Devor, Kimberly K Leslie, Brittany E Givens

Abstract readReview
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Claire E RowlandsDepartment of Chemical and Materials Engineering, University of Kentucky, 512 Administration Drive, Lexington, KY, 40506, USA.
Abigail M FolbergDepartment of Psychology, University of Nebraska at Omaha, 6100 W. Dodge Road, ASH 347E, Omaha, NE, 68182, USA.
Zachary K BeickmanDepartment of Chemical Engineering, Purdue University, 480 Stadium Mall Drive, West Lafayette, IN, 47907, USA.
Eric J DevorDepartment of Obstetrics and Gynecology, University of Iowa, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Kimberly K LeslieDivision of Molecular Medicine, Department of Internal Medicine, Department of Obstetrics and Gynecology, The University of New Mexico Comprehensive Cancer Center | The University of New Mexico Health Sciences Center, 1021 Medical Arts Ave NE, Albuquerque, NM, 87131, USA.
Brittany E GivensDepartment of Chemical and Materials Engineering, University of Kentucky, 512 Administration Drive, Lexington, KY, 40506, USA.ORCID 0000-0002-6386-7766

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Targeted Therapy for Endometrial CancerR01CA099908 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI LESLIE, KIMBERLY K. · 2002 to 2023
$5.8M
Optimal DNA Brain-Penetrating Nanoparticle (DNA-BPN) Formulation for Glioblastoma (GBM) TreatmentF31CA210610 · NCI · JOHNS HOPKINS UNIVERSITY · PI NEGRON, KARINA · 2016 to 2018
$125k
NCATS NIH HHS UL1 TR001998NCATS NIH HHS UL1TR001998NCI NIH HHS F31 CA210610NCI NIH HHS R01 CA099908NIH HHS 2R01CA 99908-16A1U.S. Department of Defense CA210610U.S. Department of Defense OC190352
6 · The paper itself

Abstract

Endometrial cancer is the most common gynecological malignancy worldwide and unfortunately has a much higher mortality rate in Black women compared with White women. Many potential factors contribute to these mortality rates, including the underlying effects of systemic and interpersonal racism. Furthermore, other trends in medicine have potential links to these rates including participation in clinical trials, hormone therapy, and pre-existing health conditions. Addressing the high incidence and disparate mortality rates in endometrial cancer requires novel methods, such as nanoparticle-based therapeutics. These therapeutics have been growing in increasing prevalence in pre-clinical development and have far-reaching implications in cancer therapy. The rigor of pre-clinical studies is enhanced by the likeness of the model to the human body. In systems for 3D cell culture, for example, the extracellular matrix mimics the tumor more closely. The increasing emphasis on precision medicine can be applied to cancer using nanoparticle-based methods and applied to pre-clinical models by using patient-derived model data. This review highlights the intersections of nanomedicine, precision medicine, and racial disparities within endometrial cancer and provides insights into reducing health disparities using recent scientific advances on the nanoscale.

Indexed as

Endometrial NeoplasmsNanomedicineAnimalsFemaleHealthcare DisparitiesHumansNanoparticlesPrejudicechemotherapeuticsendometrial cancerhealth disparitiesnanoparticlesracial bias

Identifiers

PMID37312613
PMCPMC10716380

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.